Menu

Investors

Results centre Shareholder information

Syncona is a leading FTSE250 company focused on founding, building and funding global leaders in life science

We aim to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.

2019 Full Year Results

Results centre

Net assets

£1455m

Fully diluted NAV per share

217p

NAV total return

37.9%

Capital pool available to invest in life science

£400m

New companies formed in 2019

3

Proceeds from the sale of Nightstar

£256m

FY2020 Outlook

  • Sales and earnings growth in Blue Earth
  • Strong progress in our clinical pipeline, including high impact data read outs
  • New company formations and financings; capital deployment of £100-200m

Regulatory news

View all
Autolus announces pricing of public offering
23.01.2020
View
Freeline to present further FLT180a data at EAHAD
21.01.2020
View
Notice of Capital Markets Day
21.01.2020
View
Syncona Limited - Syncona makes further $80m commitment to Freeline
19.12.2019
View

Who we are

Syncona, found, builds and funds companies in innovative areas of healthcare, targeting the superior risk-adjusted returns available from commercialising exceptional science.

Our opportunity

Today, there is rising global demand for healthcare, fuelled by ageing global populations, increased knowledge and awareness amongst the patient community, and the growing prevalence of chronic diseases.